![](https://njbmagazine.com/wp-content/uploads/2018/06/B70D3DD1-AFF8-4AEC-A76B-8E086258644D@golf.NJBIA_.local_.jpg)
Cranbury Pharmaceuticals Receives FDA Approval for First Generic Version of Emflaza Oral Suspension
On Jun 13, 2024 Cranbury Pharmaceuticals, a wholly-owned subsidiary of Tris Pharma, today announced the U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension ( …